Prevention of recurrent cystitis with intravesical instillation of hyaluronic acid Flaveran®
Authors:
Jakub Horňák; Štěpán Veselý; Klára Havlová; Marek Babjuk
Authors‘ workplace:
Urologická klinika 2. LF UK a FN Motol, Praha
Published in:
Ces Urol 2020; 24(3): 207-213
Category:
Original Articles
Overview
Horňák J, Veselý Š, Havlová K, Babjuk M. Prevention of recurrent cystitis with intravesical instillation of hyaluronic acid Flaveran®.
Objectives: Our aim was to investigate the efficacy of Flaveran®, when treating recurrent urinary tract infections (UTIs) and concomitant lower urinary tract symptoms (LUTS).
Methods: In a prospective non-randomised study, from 2018–2019, we included 7 patients aged 22 to 44 years. All were diagnosed with recurrent UTIs according to European Association of Urol‑ ogy (EAU) criteria, meaning three confirmed UTIs per year or two symptomatic UTIs in a span of six months. During a baseline examination they underwent a cystoscopy with a mucosal biopsy, ultrasound of urinary tract, urine culture, uroflowmetry and in case of persistent strong urinary urgencies cystometry. The treatment comprised of 10 intravesical instillations in one-week intervals. The efficacy was evaluated after 6 weeks, 3, 6, 12 months using the following validated questionnaires; Pelvic Pain, Urgency, and Frequency (PUF), OverActive Bladder syndrom questionare (OABq), Interstitial Cystitis Symptom Index (ICSI), Interstitial Cystitis Problem Index (ICPI) and urine cultures.
Results: Four patients had a positive baseline urine culture that was treated by a short course of antibiotic therapy. Out of 7 patients, one was excluded because of non-compliance. During the follow up we recorded two episodes of asymptomatic bacteriuria in two patients and one episode of symptomatic UTI in the third one. All cases were resolved by a course of antibiotics. Data from validated questionnaires demonstrated positive effect on LUTS and the general quality of life compared to the baseline information. Statistically significant differences were achieved during the last visit at 12th month, PUF (p < 0,05), OABq (p < 0,05), ICSI (p < 0,05) and ICPI (p < 0,05).
Conclusion: Intravesical instillation of hyaluronic acid (Flaveran®) proved to have a statistically significant effect when treating recurrent UTIs and concomitant LUTS. Over a 12-month follow-up period, we recorded only one episode of symptomatic UTI. The treatment was well tolerated and no side effects were recorded.
Keywords:
Cystitis – hyaluronic acid – intravesical instillation – recurrent urinary tract infections
Sources
1. Foxman B. Epidemiology of urinary tract infections: incidence, morbidity, and economic costs. Am J Med 2002; 113 Suppl 1 A: 5S–13S. doi: 10.1016/s0002-9343(02)01054-9.
2. Ronald A. The etiology of urinary tract infection: traditional and emerging pathogens. Am J Med 2002; 113 Suppl 1 A: 14S–19S. doi: 10.1016/s0002-9343(02)01055-0.
3. Foxman B, Gillespie B, Koopman J, et al. Risk factors for second urinary tract infection among college women. Am J Epidemiol 2000; 151(12): 1194–1205. doi: 10.1093/oxfordjournals.aje.a010170.
4. Gupta K, Trautner BW. Diagnosis and management of recurrent urinary tract infections in non‑pregnant women. BMJ 2013; 346: f3140. Published 2013 May 29. doi: 10.1136/bmj.f3140.
5. Poršová M, Kolombo I, Porš J, Pabišta R. Možnosti prevence recidivujících infekcí močových cest. Urolog. praxi 2006; 5: 204–209.
6. Ciani O, Arendsen E, Romancik M, et al. Intravesical administration of combined hyaluronic acid (HA) and chondroitin sulfate (CS) for the treatment of female recurrent urinary tract infections: a European multicentre nested case – control study. BMJ Open 2016; 6: e009669. doi: 10.1136/bmjopen-2015-009669.
7. Parsons CL, Greenspans C, Mulholland S. The primary antibacterial defense mechanism of the bladder. Invest Urol 1975; 13: 72–76.
8. Morales A, Emerson L, Nickel JC, Lundie M. Intravesical hyaluronic acid in the treatment of refractory interstitial cystitis. J Urol 1996; 156(1): 45–48.
9. Rooney P, Srivastava A, Watson L, Quinlan LR, Pandit A. Hyaluronic acid decreases IL-6 and IL-8 secretion and permeability in an inflammatory model of interstitial cystitis. Acta Biomater 2015; 19: 66–75. doi: 10.1016/j.actbio.2015. 02. 030.
10. Tay H, Parsons CL, Stein PC. Electrophysiologic monitoring of the effects of soluble virulence factors produced by Escherichia coli infection in urine. Urology 1996; 48(3): 389–392. doi: 10.1016/s0090-4295(96)00209-9.
11. Cicione A, Cantiello F, Ucciero G, et al. Intravesical treatment with highly‑concentrated hyaluronic acid and chondroitin sulphate in patients with recurrent urinary tract infections: results from a multicentre survey. Can Urol Assoc J 2014; 8(9–10): E721–E727. doi: 10.5489/cuaj.1989.
12. Goddard JC, Janssen DAW. Intravesical hyaluronic acid and chondroitin sulfate for recurrent urinary tract infections: systematic review and meta‑analysis. Int Urogynecol J 2018; 29(7): 933–942. doi: 10.1007/ s00192-017-3508-z.
13. Simmering JE, Tang F, Cavanaugh JE, Polgreen LA, Polgreen PM. The Increase in Hospitalizations for Urinary Tract Infections and the Associated Costs in the United States, 1998–2011. Open Forum Infect, DiS. 2017; 4(1): ofw281. Published 2017 Feb 24. doi: 10.1093/ofid/ofw281.
14. Albert X, Huertas I, Pereiró II, et al. Antibiotics for preventing recurrent urinary tract infection in non‑pregnant women. Cochrane Database Syst Rev 2004; 2004(3): CD001209. doi: 10.1002/14651858.CD001209. pub2.
15. Rejchrt M, Havlová K, Kříž J. Prevence recidivujících uroinfekcí intravezikální instilací kyseliny hyaluronové a chondroitinsulfátu u pacientů po míšním poranění. Urol. praxi 2015; 16: 43.
16. Erikse BA. Randomized, open, parallel‑group study on the preventive effect of an estradiol‑releasing vaginal ring (Estring) on recurrent urinary tract infections in postmenopausal women. Am J Obstet Gynecol 1999; 180(5): 1072–1079. doi: 10.1016/s0002-9378(99)70597-1.
17. Raz R, Stamm WE. A controlled trial of intravaginal estriol in postmenopausal women with recurrent urinary tract infections. N Engl J Med 1993; 329(11): 753–756. doi: 10.1056/NEJM199309093291102.
18. Damiano R, Quarto G, Bava I, et al. Prevention of recurrent urinary tract infections by intravesical administration of hyaluronic acid and chondroitin sulphate: a placebo‑controlled randomised trial [published correction appears in Eur Urol. 2011 Jul; 60(1): 193]. Eur Urol 2011; 59(4): 645–651. doi: 10.1016/j.eururo.2010.12.039.
19. Arya LA, Northington GM, Asfaw T, Harvie H, Malykhina A. Evidence of bladder oversensitivity in the absence of an infection in premenopausal women with a history of recurrent urinary tract infections. BJU Int. 2012; 110(2): 247–251. doi: 10.1111/j.1464-410X.2011.10766.x.
20. Gülpınar O, Kayış A, Süer E, et al. Clinical comparision of intravesical hyaluronic acid and hyaluronic acid‑chondroitin sulphate therapy for patients with bladder pain syndrome/interstitital cystitis. Can Urol Assoc J 2014; 8(9–10): E610–E614. doi: 10.5489/cuaj.2036.
21. De Vita D, Giordano S. Effectiveness of intravesical hyaluronic acid/chondroitin sulfate in recurrent bacterial cystitis: a randomized study. Int Urogynecol J 2012; 23(12): 1707–1713. doi: 10.1007/s00192-012-1794-z.
Labels
Paediatric urologist Nephrology UrologyArticle was published in
Czech Urology
2020 Issue 3
Most read in this issue
- Minimally invasive surgical methods for the treatment of benign prostatic hyperplasia, as an alternative to classic desobstructive procedures
- Prevention of recurrent cystitis with intravesical instillation of hyaluronic acid Flaveran®
- Prostate carcinoma metastasis to the testis
- Bladder neck preservation with RARP